Communicating Risk-Based Justifications to Regulatory Agencies
Communicating risk-based justifications to regulatory agencies is a critical aspect of modern pharmaceutical stability testing. With guidelines like ICH Q9 and ICH Q1D encouraging science- and risk-based approaches, regulators now expect companies to provide solid rationale—not just data—for their testing strategies. Whether it’s bracketing, matrixing, or other streamlined stability designs, the clarity and robustness of…
Read More “Communicating Risk-Based Justifications to Regulatory Agencies” »